On the research front last week, China-based biotech Remegen released positive Phase III results for its telitacicept in ...

The US subsidiary of Chinese biotech VelaVigo Cayman Limited has announced its second out-licensing agreement of a ...

The National Board of Health and Welfare will pay 80 million kronor ($8.3 million) to the national initiative Genomic ...

London, UK-based Alis Biosciences, an investment fund focused on returning capital to investors that is currently trapped in ...

The DESTINY-Breast09 Phase III trial of AstraZeneca (LSE: AZN) and Daiichi Sankyo’s (TYO: 4568) Enhertu (trastuzumab ...

The US Food and Drug Administration (FDA) has granted another approval for Dupixent (dupilumab), for the treatment of adults ...

Earendil Labs, a US AI-driven R&D next-generation biologics therapeutics start-up, has entered into a license agreement with French pharma major Sanofi (Euronext: SAN) for two potential first-in-class ...

In keeping with US Department of Health and Human Services Secretary Robert F Kennedy Jr’s promise to carry out the ...

Dutch gene therapy company uniQure (Nasdaq: QURE) announced that the US Food and Drug Administration (FDA) has granted ...

US President Donald Trump issued an executive order on April 15 listing several potential policy changes aimed at lowering US ...

The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) Injection 8mg, submitted by US biotech ...

Australian clinical-stage biotech Neurizon Therapeutics (ASX: NUZ & NUZOA), which is advancing innovative treatments for ...